XFOR
X4 Pharmaceuticals, Inc.3.7100
-0.0500-1.33%
Dec 16, 4:00:00 PM EST
Earnings Call Transcripts
This Quarter (Q4 '25)
No earnings call transcript available yet
Last Quarter (Q3 '25)
No earnings call transcript available
Key Stats
Market Cap
324.39MP/E (TTM)
-Basic EPS (TTM)
-8.92Dividend Yield
0%Recent Filings
8-K
X4 restructures, funds trial
X4 Pharmaceuticals restructured operations in Q3 2025, slashing its workforce by 50% to save $13 million annually while prioritizing the 4WARD Phase 3 trial for mavorixafor in chronic neutropenia over WHIM syndrome commercialization. Two financings raised $240.3 million, extending cash runway to end-2028 for trial completion and potential launch. Q3 net loss narrowed to $29.8 million from $36.7 million year-over-year. Restructuring sharpens focus amid trial risks.
10-Q
Q3 FY2025 results
X4 Pharmaceuticals posted Q3 revenue of $1.8M, up 215% y/y from $0.6M, driven by $1.6M in U.S. product sales of XOLREMDI and $0.2M from the Norgine license deal, while YTD revenue soared to $32.5M from $28.3M in licensing fees plus $4.3M in product sales, a 2,796% y/y jump. Operating losses narrowed to $27.5M from $34.5M y/y, thanks to 30% and 50% workforce cuts that trimmed R&D to $17.3M and SG&A to $11.6M, though net loss widened to $29.8M from $36.7M due to a $0.7M warrant liability hit. Cash climbed to $122.2M with $81M from an August private placement, bolstering the $75M Hercules debt due 2027 at 11.4% effective rate; free cash flow not disclosed in the 10-Q. The January Norgine pact grants exclusive European rights for €28.5M upfront plus milestones up to €226M and mid-20s royalties. Yet clinical trial delays could stall mavorixafor's chronic neutropenia push.
8-K
X4 cuts workforce 50% for trial focus
X4 Pharmaceuticals announced a strategic restructuring on September 17, 2025, slashing its workforce by 50% to sharpen focus on the 4WARD Phase 3 trial for chronic neutropenia, yielding $13 million in annualized cost savings but incurring $3.3 million in severance charges. The move triggered exits of the COO, CCO, Chief Legal Officer, and CMO, with John Volpone stepping in as COO alongside his president role and Dr. Adam Craig overseeing clinical development. Restructuring sharpens execution. Yet actual savings hinge on unproven assumptions, risking operational hiccups.
8-K
Board resignations at X4
X4 Pharmaceuticals saw two board members, David McGirr and R. Keith Woods, resign effective August 22, 2025, without any disagreements over operations or policies. Michael Wyzga stepped up as audit committee chair, joined by Francoise de Craecker and Gary Bridger. Board shakeups like this keep governance fluid. No further impacts disclosed.
8-K
X4 closes $85M funding
X4 Pharmaceuticals closed an upsized $85 million private placement on August 13, 2025, selling 11 million shares and pre-funded warrants for 48.9 million more, boosting fully diluted shares to 87.2 million. Led by Coastlands Capital with support from Empery, Bain, NEA, and others, the deal funds Phase 3 enrollment in mavorixafor's 4WARD trial for chronic neutropenia while advancing XOLREMDI commercialization. Cash bolsters runway, yet dilution pressures near-term stock value.
CCCC
C4 Therapeutics, Inc.
2.26-0.17
KYMR
Kymera Therapeutics, Inc.
84.19-1.49
LXRX
Lexicon Pharmaceuticals, Inc.
1.20-0.03
RXRX
Recursion Pharmaceuticals, Inc.
4.20+0.00
VRTX
Vertex Pharmaceuticals Incorpor
454.96-0.75
XERS
Xeris Biopharma Holdings, Inc.
7.10+0.05
XLO
Xilio Therapeutics, Inc.
0.65+0.00
XNCR
Xencor, Inc.
16.55-0.24
XRTX
XORTX Therapeutics Inc.
0.59-0.01
XTLB
XTL Biopharmaceuticals Ltd.
0.78-0.03